CSF3 and COVID-19: Finally, there is also some evidence that G-CSF administration could lead to more severe outcomes with COVID-19, potentially due to increased pulmonary inflammation and macrophage activation (37, 45), and that patients with severe COVID-19 infection may develop a “cytokine storm” characterized by increased levels of inflammatory markers, including G-CSF (46).